Neuromuscular Re-education on Pain, ROM and Disability in Cervical Radiculopathy

June 8, 2026 updated by: Riphah International University

Effects of Neuromuscular Re-education on Pain, Range of Motion and Disability in Patients With Cervical Radiculopathy

This study explores the effectiveness of Neuromuscular Re-education compared to conventional therapies in managing pain, range of motion, and disability in patients with Cervical Radiculopathy

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The study identifies a gap in the current literature surrounding the effectiveness of neuromuscular re-education interventions in targeting pain reduction, disability improvement, and enhancement of range of motion for CR patients. Previous studies emphasize conventional methods, such as proprioceptive neuromuscular facilitation and manual therapy, with a general focus on motor control and postural re-education. However, the precise benefits of structured NMR exercises tailored to CR symptoms, particularly targeting proprioceptive training and functional task simulation, are less explored, especially compared to traditional interventions like heat/cold application or general strengthening

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
52

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab Province
      • Sialkot, Punjab Province, Pakistan, 54500
        • Recruiting
        • National hospital sialkot
        • Contact:
        • Principal Investigator:
          • Sofia Rehman, MS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants of Age between 30 and 50 years old.
  • Participants of both gender included.
  • Participants having Unilateral upper extremity pain, paresthesia, or numbness
  • Participants with Four positive findings required:
  • Positive Spurling's test
  • Positive distraction test
  • Positive upper limb tension test
  • Ipsilateral cervical rotation less than 60 degrees
  • Participants must have experienced pain for at least 3 months.
  • Participants must have a pain score of 4 to 6 on the 0-10 scale

Exclusion Criteria:

  • Participants having prior cervical spine surgery.
  • Participants with Cervical vertebral fracture
  • Participants with severe osteoporosis, rheumatic disease, shoulder disease, or infection will be excluded.
  • Participants with vertebro-basilar artery insufficiency and diabetic neuropathy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Neuromuscular Re-education Group
postural training exercises, proprioceptive tasks, Dynamic control exercises, eye-head coordination tasks
Other: Neuromuscular Re education

A. Postural training and functional task simulation(chin tuck, Shoulder blade squeeze, reaching, carrying, lifting tasks) Proprioceptive tasks( single leg stance with head movement), deep cervical strengthening.

3 sessions per week, 30 minutes per session (10 mint each component),10 repetition per set, 2 set, 10 second Resting interval Resting period: 1 mint to next exercise
Active Comparator: Conventional Physical Therapy
Electrotherapy, Manual Therapy Techniques
Other: Conventional Physical Therapy
  • TENS and hot pack for 10 to 15 minutes
  • Manual therapy techniques (e.g., mobilizations grade II). 5 to 10 repetition
  • Cervical isometric exercises 10 reps
  • General education on posture and ergonomics guidelines
  • Frequency: 3 sessions per week
  • Duration: 50 minutes per session, 10 mint each component
  • Repetition: 10 repetition per set, 2 set , 10 second resting interval
  • Resting period: 1 mint to next exercise

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Goniometer
Time Frame: 8th Week
A goniometer is used to measure cervical range of motion (ROM) by aligning its fulcrum over a bony landmark (like the C7 vertebrae or external auditory meatus) and its arms with other bony landmarks (such as the nose, acromion, or sternal notch) to measure the angle of movement in degrees.
8th Week
NDI (Neck Disability Index)
Time Frame: 8th week
The NDI is a 10-item questionnaire that assesses how neck pain affects daily activities(28). The Neck Disability Index (NDI) measures neck-specific disability through a 10-item questionnaire assessing pain and daily activities like personal care, lifting, and concentration. Scores range from 0-50 (or 0-100%), with higher scores indicating greater disability
8th week
Numeric Pain Rate Scale
Time Frame: 8th week
The Numerical Pain Rating Scale (NPRS) has been used to assess the level of pain patients experience. It can be used to assess pain either verbally or through a self completion questionnaires. Patients are asked to circle a number on a scale that best describes the pain the experience. Patients are asked to recall from the pain scale from 0 to 10. 0 equals No pain, 1-3 equals Mild pain, 4-6 equals Moderate pain, 7-9 equals Severe pain, and 10 equals Very Severe pain. NPRS shows strong test-retest score even in illiterate and literate patients
8th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Javeria Ghazal, MS, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 16, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 23, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 27, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 1, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR & AHS/24/0298

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings